Table 5.
Comparison of systemic therapy and recurrence patterns between responders and non-responders to the last line systemic therapy before RFA treatment.
| Variable | Responder (PR) | Non-Responder (SD,PD) | p-values | |
|---|---|---|---|---|
| Number of patients (%) | 63 (56) | 50 (44) | ||
| Systemic therapy received before RFA | ||||
| Median number of lines (range) | 1.2 (1-3) | 1.8 (1-3) | <0.001 | |
| ≥2 lines of chemotherapy, n (%) | 14 (22.2) | 33 (66.0) | <0.001 | |
| Oxaliplatin used in last line | 30 (47.6) | 23 (46.0) | 0.864 | |
| Irinotecan used in last line | 22 (34.9) | 20 (40.0) | 0.579 | |
| Bevacizumab used in last line | 12 (19.1) | 12 (24.0) | 0.523 | |
| Cetuximab used in last line | 5 (7.9) | 3 (6.0) | 1.000 | |
| Systemic therapy received before and after RFA | ||||
| Median number of lines (range) | 2.9 (1-5) | 3.2 (2-5) | 0.011 | |
| Oxaliplatin | 57 (90.5) | 49 (98.0) | 0.131 | |
| Irinotecan | 57 (90.5) | 50 (100) | 0.033 | |
| Bevacizumab | 37 (58.7) | 26 (52.0) | 0.474 | |
| Cetuximab | 10 (15.9) | 13 (26.0) | 0.184 | |
| Timing of recurrence after RFA | ||||
| Median time (range) to recurrence, months | 10.0 (9.0-12.0) | 4.0 (3.0-5.0) | <0.001 | |
| Time to recurrence ≤ 6months (early) | 13 (23.6) | 39 (78.0) | <0.001 | |
| Time to recurrence > 6 months (late) | 42 (76.4) | 11 (22.0) | ||
| Patterns of recurrence after RFA | ||||
| No recurrence | 8 (12.8) | 0 (0) | 0.009 | |
| Any local RFA-site recurrence (LR) | 4 (7.3) | 12 (24.0) | 0.028 | |
| LR, only | 2 (3.2) | 3 (6.0) | 0.867 | |
| Any intrahepatic recurrence | 43 (68.2) | 45 (90.0) | 0.039 | |
| Liver, only | 34 (61.8) | 26 (52.0) | 0.310 | |
| Any extrahepatic recurrence | 19 (30.2) | 22 (44.0) | 0.581 | |
| Lung, only | 10 (18.2) | 1 (2.0) | 0.007 | |
| Number of recurrence sites | ||||
| ≥2 sites (disseminated) | 9 (16.4) | 20 (40.0) | 0.007 | |
PD, progressive disease; PR, partial remission; RFA, radiofrequency ablation; SD, stable disease.